Amrubicin

Jump to: navigation, search
Amrubicin
Amrubicin.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H25NO9
Molar mass483.46 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Amrubicin

Articles

Most recent articles on Amrubicin

Most cited articles on Amrubicin

Review articles on Amrubicin

Articles on Amrubicin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Amrubicin

Images of Amrubicin

Photos of Amrubicin

Podcasts & MP3s on Amrubicin

Videos on Amrubicin

Evidence Based Medicine

Cochrane Collaboration on Amrubicin

Bandolier on Amrubicin

TRIP on Amrubicin

Clinical Trials

Ongoing Trials on Amrubicin at Clinical Trials.gov

Trial results on Amrubicin

Clinical Trials on Amrubicin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Amrubicin

NICE Guidance on Amrubicin

NHS PRODIGY Guidance

FDA on Amrubicin

CDC on Amrubicin

Books

Books on Amrubicin

News

Amrubicin in the news

Be alerted to news on Amrubicin

News trends on Amrubicin

Commentary

Blogs on Amrubicin

Definitions

Definitions of Amrubicin

Patient Resources / Community

Patient resources on Amrubicin

Discussion groups on Amrubicin

Patient Handouts on Amrubicin

Directions to Hospitals Treating Amrubicin

Risk calculators and risk factors for Amrubicin

Healthcare Provider Resources

Symptoms of Amrubicin

Causes & Risk Factors for Amrubicin

Diagnostic studies for Amrubicin

Treatment of Amrubicin

Continuing Medical Education (CME)

CME Programs on Amrubicin

International

Amrubicin en Espanol

Amrubicin en Francais

Business

Amrubicin in the Marketplace

Patents on Amrubicin

Experimental / Informatics

List of terms related to Amrubicin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in Japan since 2002 by Sumitomo Pharmaceuticals under the brand name Calsed.[2]

Amrubicin acts by inhibiting topoisomerase II, and has been compared in clinical trials with topotecan, a Topoisomerase I inhibitor.[3] [4]

It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6]

References

  1. Ueoka H, Ohnoshi T, Kimura I (November 1992). "[New anthracycline analogues in the treatment of lung cancer]". Gan To Kagaku Ryoho (in Japanese). 19 (13): 2146–9. PMID 1332624.
  2. Sumitomo Pharmaceuticals Co., Ltd. (2003). "CALSED for Injection (English)" (PDF). Retrieved 2008-08-17.[dead link]
  3. Celgene Corporation (2008). "Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". Retrieved 2009-07-10.
  4. Medical News Today (2007). "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer". Retrieved 2009-07-10.
  5. Ohmori H, Tsushima T, Kobashi K (April 1996). "[Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]". Gan To Kagaku Ryoho (in Japanese). 23 (5): 601–6. PMID 8678519.
  6. Tsushima K, Sakata Y, Munakata A; et al. (June 1991). "[A phase II study of SM-5887 for advanced gastric cancer]". Gan To Kagaku Ryoho (in Japanese). 18 (7): 1151–4. PMID 1647150.

Linked-in.jpg